Tango Therapeutics (TNGX) EBIT Margin: 2020-2025
Historic EBIT Margin for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to 26.15%.
- Tango Therapeutics' EBIT Margin rose 30941.00% to 26.15% in Q3 2025 from the same period last year, while for Sep 2025 it was -165.91%, marking a year-over-year increase of 15609.00%. This contributed to the annual value of -346.09% for FY2024, which is 3351.00% down from last year.
- Latest data reveals that Tango Therapeutics reported EBIT Margin of 26.15% as of Q3 2025, which was up 102.03% from -1,287.87% recorded in Q2 2025.
- In the past 5 years, Tango Therapeutics' EBIT Margin ranged from a high of 26.15% in Q3 2025 and a low of -1,287.87% during Q2 2025.
- Over the past 3 years, Tango Therapeutics' median EBIT Margin value was -525.25% (recorded in 2023), while the average stood at -517.92%.
- Over the last 5 years, Tango Therapeutics' EBIT Margin had its largest YoY gain of 30,941bps in 2025, and its largest YoY loss of 113,918bps in 2025.
- Quarterly analysis of 5 years shows Tango Therapeutics' EBIT Margin stood at -384.60% in 2021, then crashed by 9,219bps to -476.79% in 2022, then slumped by 16,790bps to -644.69% in 2023, then crashed by 34,900bps to -993.68% in 2024, then spiked by 30,941bps to 26.15% in 2025.
- Its EBIT Margin was 26.15% in Q3 2025, compared to -1,287.87% in Q2 2025 and -788.76% in Q1 2025.